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ABSTRACT
Estrogen receptor a (ERa) plays critical roles in
development and progression of breast cancer.
Because ERa activity is strictly dependent upon
the interaction with coregulators, coregulators are
also believed to contribute to breast tumorigenesis.
Cell Cycle and Apoptosis Regulator 1 (CCAR1) is an
important co-activator for estrogen-induced gene
expression and estrogen-dependent growth of
breast cancer cells. Here, we identified Deleted
in Breast Cancer 1 (DBC1) as a CCAR1 binding
protein. DBC1 was recently shown to function as a
negative regulator of the NAD-dependent protein
deacetylase SIRT1. DBC1 associates directly with
ERa and cooperates synergistically with CCAR1
to enhance ERa function. DBC1 is required for
estrogen-induced expression of a subset of ERa
target genes as well as breast cancer cell prolifer-
ation and for estrogen-induced recruitment of ERa
to the target promoters in a gene-specific manner.
The mechanism of DBC1 action involves inhibition
of SIRT1 interaction with ERa and of SIRT1-
mediated deacetylation of ERa. SIRT1 also
represses the co-activator synergy between DBC1
and CCAR1 by binding to DBC1 and disrupting its
interaction with CCAR1. Our results indicate that
DBC1 and SIRT1 play reciprocal roles as major
regulators of ERa activity, by regulating DNA
binding by ERa and by regulating co-activator
synergy.
INTRODUCTION
Estrogen receptor a (ERa) is a member of the superfamily
of nuclear receptors (NRs), and it functions as a
ligand-dependent transcription factor that mediates the
diverse biological effects of estrogens, including develop-
ment, maintenance of female reproductive functions and
the etiology of breast cancer (1). NRs consist of a variable
N-terminal region, a DNA binding domain (DBD), a
hinge region and a conserved ligand binding domain
(LBD). ERa and other NRs bind to hormone response
elements in their target promoters and regulate the expres-
sion of a variety of target genes through the recruitment
of co-regulators (co-activators and co-repressors) that
mediate local chromatin remodeling as well as communi-
cations with the RNA polymerase II (Pol II)-associated
basal transcription machinery (2). The p160 co-activators
(e.g. SRC-1, GRIP1 and AIB1) interact directly with
hormone-activated NRs and serve as protein scaffolds
for the assembly of multicomponent co-activator com-
plexes on target promoters. p160 co-activators recruit sec-
ondary co-activators, including histone acetyltransferase
p300/CBP, histone methyltransferase CARM1 and
CoCoA, and act synergistically with secondary
co-activators to enhance NR function (2,3). Mediator,
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act as a molecular bridge between NRs and Pol
II-associated basal transcription machinery (4). Recently,
we identiﬁed cell cycle and apoptosis regulator 1 (CCAR1)
as a CoCoA binding protein (5). CCAR1 interacts with
ERa and cooperates synergistically with components
of the p160 co-activator complex. CCAR1 is important
for estrogen-induced expression of ERa target genes and
estrogen-dependent growth of breast cancer cells. CCAR1
associates with components of the Mediator complex and
facilitates recruitment of Mediator complex to the
promoter of target genes by providing a physical link
between p160 co-activator and Mediator complexes. In
addition, CCAR1 binds to and cooperates synergistically
with b-catenin as a secondary co-activator for LEF1 (6).
Thus, CCAR1 is a physiologically relevant part of several
transcriptional activation processes.
In addition to co-regulators, post-translational modiﬁ-
cations are also crucial for the regulation of NR function
such as DNA binding, interaction with co-regulators, sta-
bility and subcellular localization (7). For example, ERa
is acetylated by p300 at several lysine residues in the
hinge region, and the acetylation enhances DNA binding
and trans-activation activities of ERa (8). Although, a
previous report suggested that the acetylation of ERa is
reversed by cellular deacetylases, including Trichostatin A
(TSA)-sensitive enzymes (classes I and II deacetylases) and
nicotinamide-sensitive enzymes (class III deacetylases such
as SIRT1), their roles in ERa-mediated transcription is
still largely unknown.
To further characterize the mechanism by which
CCAR1 contributes to transcriptional activation, we
used a biochemical approach to identify CCAR1-
associated proteins and found deleted in breast cancer 1
(DBC1; also known as KIAA1967 and p30 DBC) as a
CCAR1-interacting protein. DBC1 was originally cloned
from a region 8p21 that was homozygously deleted in
breast cancer (9,10). Recently, DBC1 has been reported
as a negative regulator of SIRT1 (11,12). DBC1 interacts
with the catalytic domain of SIRT1, inhibits its
deacetylase activity, and then increases acetylation levels
of p53, thereby enhancing p53-mediated apoptosis.
However, despite the tumor suppressor function of
DBC1, several studies reported increased expression of
DBC1 in breast carcinoma (13,14), suggesting that
DBC1 may participate in the development and progres-
sion of breast cancer. In this study, we show that DBC1
associates and cooperates synergistically with CCAR1
to enhance ERa function. DBC1 is required for the ex-
pression of a subset of ERa target genes and estrogen-
dependent growth of breast cancer cells. SIRT1
deacetylates ERa, causing reduced DNA binding. DBC1
inhibits SIRT1-mediated deacetylation and restores
optimal recruitment of ERa to target gene promoters.
SIRT1 also represses the co-activator synergy between
CCAR1 and DBC1 by competing with CCAR1 for
binding to DBC1 and thereby disrupting the DBC1–
CCAR1 interaction. Collectively, our results suggest that
DBC1 and SIRT1 play reciprocal roles in the regulation of
ERa activity and co-activator synergy.
MATERIALS AND METHODS
Isolation of DBC1
HeLa S cells were infected with lentiviruses expressing
FLAG-tagged CCAR1 and selected with hygromycin.
A stable cell line expressing FLAG-CCAR1 (HeLa
S-FLAG-CCAR1) was grown in spinner culture in
DMEM supplemented with 10% bovine calf serum.
Preparation of nuclear extracts and M2-agarose afﬁnity
chromatography were performed as described previously
(15). After extensive washings, the bound proteins were
eluted using 3 FLAG peptide. The puriﬁed CCAR1-
associated proteins were identiﬁed by mass spectrometry
performed at the Taplin Biological Mass Spectrometry
Facility at Harvard Medical School.
Protein interaction assays and immunoblot
For GST pull-down assays, HA or V5 epitope-tagged
proteins were synthesized in vitro by using TNT-Quick
coupled transcription/translation system (Promega)
and incubated with immobilized GST-fusion proteins.
After washing, bound proteins were analyzed by
immunoblot with anti-HA or anti-V5 antibody. For co-
immunoprecipitation (CoIP) assays, COS-7, 293T or
MCF-7 cell extracts were immunoprecipitated by speciﬁc
antibodies or control IgG and protein G Dynabeads
(Invitrogen) as indicated in ﬁgure legends.
Acetylation and deacetylation assays
Expression plasmids for GST-ER-V5/His, HA-p300,
FLAG-SIRT1 and HA-DBC1 were transfected into
293T cells as indicated in the ﬁgure legends. After 36h
of transfection, the cells were treated with 0.5mM TSA
(Sigma) and 100nM E2 for 12h and then lysed in
FLAG lysis buffer (50mM Tris–HCl, pH 8.0, 137mM
NaCl, 1mM ethylenediaminetetraacetic acid (EDTA),
1% Triton-X 100, 0.2% Sarkosyl, 10% glycerol) supple-
mented with 0.5mM TSA and protease inhibitor cocktail
(Roche). ERa was immunoprecipitated with anti-ERa
antibody, and acetylation levels were determined by
immunoblot with anti-acetyl lysine antibody. In vitro
deacetylation assays were performed according to the pro-
cedure described previously (11,12). 293T cells were tran-
siently transfected with FLAG-tagged expression plasmids
for SIRT1 and DBC1. Transfected cells were lysed in
BC500 buffer (20mM Tris–HCl pH 7.6, 500mM NaCl,
0.2mM EDTA, 0.5% Triton X-100, 10% glycerol and
protease inhibitor cocktail), and the cell lysates were
immunoprecipitated with anti-FLAG M2 agarose beads.
After three washes with BC500, followed by two washes
with BC100 (20mM Tris-HCl pH 7.6, 100mM NaCl,
0.2mM EDTA, 0.1% Triton X-100, 10% glycerol and
protease inhibitor cocktail), the bound proteins were
eluted with 3 FLAG peptide in BC100. FLAG-tagged
ERa and HA-tagged p300 were transiently transfected in
293T cells. After 48h of transfection, cells were treated
with 100nM E2 and 0.5mM TSA for 4h and lysed in
FLAG lysis buffer. The whole-cell lysates were
immunoprecipitated with anti-FLAG M2 agarose beads,
and the beads were washed with FLAG lysis buffer,
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acetylated ERa was then eluted with 3 FLAG peptide
and incubated with puriﬁed SIRT1 and DBC1 in SIRT1
reaction buffer (50mM Tris–HCl pH 8.8, 50mM NaCl,
4mM MgCl2, 0.5mM DTT, 0.02% NP-40, 5% glycerol
and 1mM NAD
+) for 3h at 30C. The reactions were
analyzed by immunoblot with anti-acetyl lysine antibody.
Plasmids and antibodies, cell culture and transient
transfection, MTT and ﬂow cytometric analysis, chroma-
tin immunoprecipitation (ChIP) assays, RNA interference
and real-time qRT–PCR, and statistical analysis are ex-
plained in detail in Supplementary Data.
RESULTS
Identiﬁcation of DBC1 as a CCAR1-interacting protein
To identify proteins associated with CCAR1, we genera-
ted a HeLa cell line stably expressing FLAG-tagged
CCAR1 and puriﬁed CCAR1-associated proteins from nu-
clear extracts using anti-FLAG M2-agarose beads. Several
proteins were selectively co-puriﬁed with FLAG-CCAR1
but not with the FLAG control. We analyzed these
CCAR1-associated proteins by tandem mass spectrometry
and identiﬁed DBC1 as a CCAR1-associated protein
(Figure 1A). Other proteins associated with CCAR1 are
listed in Supplementary Table S1. DBC1 shows signiﬁcant
homology to CCAR1 (10,16) and, like CCAR1, has a
nuclear localization signal (NLS), a Nudix domain, an
EF hand, and a coiled-coil domain (Figure 1B). We next
veriﬁed the association between endogenous CCAR1 and
DBC1 in ER-positive MCF-7 breast cancer cells by CoIP
assays. Consistent with the mass spectrometry data, en-
dogenous DBC1 was detected in the immunoprecipitates
of endogenous CCAR1 (Figure 1C). Similarly, HA-tagged
CCAR1 was co-immunoprecipitated speciﬁcally with
V5-tagged DBC1 from extracts of transiently transfected
COS-7 cells (Supplementary Figure S1A). In addition,
in vitro GST pull-down assays conﬁrmed the interaction
between CCAR1 and DBC1 (Supplementary Figure S1B),
suggesting that CCAR1 interacts directly with DBC1.
Since DBC1 shares homology with CCAR1, which was
identiﬁed as a CoCoA AD binding protein (5), we next
asked whether DBC1 might also interact with CoCoA
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Figure 1. DBC1 interacts with CCAR1 and functions as an ERa co-activator. (A) Nuclear extracts from HeLa S cells stably expressing
FLAG-CCAR1 were immunoprecipitated with anti-FLAG M2 agarose. Bound proteins were eluted with FLAG peptide, resolved on 4%–12%
gradient Bis-Tris gels, silver-stained, and analyzed by mass spectrometry. The identiﬁed peptides of DBC1 are listed. (B) Schematic representation of
DBC1 and CCAR1 structures. NLS, nuclear localization signal; LZ, leucine zipper motif; SAP, SAP domain; Nudix, Nudix hydrolase domain. (C)
Endogenous interaction between DBC1 and CCAR1. MCF-7 cell lysates were immunoprecipitated with anti-CCAR1 antibody or normal rabbit IgG,
followed by immunoblot with the indicated antibodies. (D) CV-1 cells were transfected with pHE0 encoding ERa (2ng) and MMTV(ERE)-LUC
reporter in combination with various amounts (200, 400 and 800ng) of pSG5.HA-DBC1 and grown in medium containing or lacking 100nM
estradiol (E2) before conducting luciferase assays on cell extracts. Data are means±SD (n=3). (E) Synergy between CCAR1 and DBC1. Transient
transfections were performed as described in D. Expression vectors: pSG5.HA-CCAR1 (200ng), pSG5.HA-DBC1 (200 and 400ng). Data are
means±SD (n=3).
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(Supplementary Figure S1C and S1D). In addition,
DBC1 speciﬁcally interacted with CoCoA AD but not
with the central coiled-coil or N-terminal domains of
CoCoA (Supplementary Figure S1E). Since a previous
study showed that ERa interacts with DBC1 (17), we
conﬁrmed the interaction between ERa and DBC1.
DBC1 bound to ERa in a hormone-independent manner
in GST pull-down assays and in CoIP experiments per-
formed with both overexpressed and endogenous proteins
(Supplementary Figure S1F–S1H). Taken together, these
ﬁndings demonstrate that DBC1 can interact with
CCAR1, ERa and CoCoA.
DBC1 functions as a NR co-activator and cooperates
synergistically with CCAR1
Since DBC1 interacts with CCAR1 and ERa, we tested
whether DBC1 can function as a co-activator for ERa.I n
reporter gene assays, DBC1 enhanced the hormone-
dependent activity of exogenous ERa in a dose-dependent
manner (Figure 1D). We also performed similar reporter
gene assays with androgen receptor (AR), glucocorticoid
receptor (GR), thyroid hormone receptor b1 (TR) and
their reporters to test the co-activator activity of DBC1
for other NRs (Supplementary Figure S2A). Consistent
with a previous report (18), DBC1 enhanced the
hormone-induced AR activity. DBC1 also stimulated
the transcriptional activities of GR and TR in a
hormone-dependent manner, suggesting that DBC1 func-
tions as a NR co-activator. We next tested whether DBC1
and CCAR1 can function synergistically as co-activators
for ERa in reporter gene assays (Figure 1E). As expected,
CCAR1 and DBC1 individually enhanced the transcrip-
tional activity of ERa. In addition, co-expression of
CCAR1 and DBC1 enhanced ERa function in a synergis-
tic manner. Similarly, DBC1 cooperated synergistically
with CCAR1 to enhance endogenous ERa activity in
MCF-7 and T47D cells (Supplementary Figure S2B).
The transcriptional activities of AR, GR and TR were
also synergistically enhanced by co-expression of
CCAR1 and DBC1 (Supplementary Figure S2C).
Together, these results suggest that DBC1 functions as a
co-activator for multiple NRs and cooperates synergistic-
ally with CCAR1.
DBC1 is required for E2-induced expression of a subset
of ERa target genes
To further assess the functional involvement of DBC1 in
ERa-mediated transcription, the expression of DBC1 was
reduced by RNA interference (RNAi). To avoid possible
off-target effects caused by the DBC1 RNAi, we used two
different siRNA sequences that target different regions of
DBC1 mRNA (Supplementary Figure S3A). When DBC1
mRNA and protein levels were speciﬁcally reduced
in MCF-7 cells by siRNA transfection, estradiol
(E2)-induced expression of the endogenous pS2 gene was
signiﬁcantly inhibited compared with the results using
non-speciﬁc (NS) siRNA (Supplementary Figure S3B
and Figure 2A). In seven such independent experiments,
we found a direct linear relationship between the levels of
DBC1 and pS2 mRNAs (Supplementary Figure S3C).
Similarly, E2-induced expression of a transiently trans-
fected reporter gene in MCF-7 cells was inhibited by the
DBC1-speciﬁc siRNA (siDBC1) but not by siNS
(Supplementary Figure S3D). As shown in Figure 2A,
depletion of DBC1 also repressed the E2-induced expres-
sion of GREB1, c-Myc, CTSD and CCND1 genes.
Intriguingly, the expression of PgR was not affected
under the same conditions, suggesting that DBC1 is
required for the expression of a subset of ERa target
genes.
To further explore the functional link between CCAR1
and DBC1, the expression of DBC1 and CCAR1 was
reduced either individually or in combination using
DBC1 siRNA in MCF-7 cells infected with lentivirus ex-
pressing a non-speciﬁc (shNS) or CCAR1 shRNA
(shCCAR1). The protein levels of DBC1 and/or CCAR1
were speciﬁcally reduced under these experimental condi-
tions (Figure 2B). As expected, E2-induced levels of pS2
and CTSD mRNAs were reduced by individual
knockdown of DBC1 and CCAR1, and their expression
was further reduced by simultaneous depletion of DBC1
and CCAR1 (Figure 2C). However, neither single nor
double depletion of DBC1 and CCAR1 affected PgR
gene expression. Again, these results suggest that DBC1
and CCAR1 cooperate to enhance the expression of a
subset, but not all, of ERa target genes.
To assess the potential relevance of our results to the
biology of breast cancer cells, we examined the effect of
reduced DBC1 levels on E2-stimulated cell proliferation in
MCF-7 cells infected with lentivirus expressing a shNS
or DBC1 shRNA (shDBC1). E2 treatment-stimulated
proliferation of MCF-7/shNS cells, but E2 stimulation
of MCF-7 cell growth was attenuated by reduction of
DBC1 expression (Figure 2D). To study the potential
mechanistic defect underlying the observed effect on cell
proliferation, the cell cycle proﬁle was examined. As
expected, E2-treatment of MCF-7/shNS cells resulted in
an increase in the combined percentage of S-phase and
G2/M-phase cells (from 25.7% to 42.94%). In contrast,
only 33.93% of E2-stimulated MCF-7/shDBC1 cells were
found in S-phase and G2/M-phase (Supplementary Figure
S3E). Thus, these results suggest that DBC1 plays a
critical role in E2-stimulated proliferation of breast
cancer cells and in promoting cell cycle progression.
DBC1 is recruited to selective ERa target gene promoters
and is required for optimal recruitment of ERa to
the promoters
To examine whether DBC1 is directly involved in
ERa-mediated transcription, we performed ChIP assays
in MCF-7 cells (Figure 3A). ERa, AIB1, CoCoA and
CCAR1 were recruited to the ER binding site associated
with the pS2 gene promoter in a hormone-dependent
manner, as reported previously (5). E2 treatment also
led to the recruitment of DBC1 to the pS2 promoter,
whereas the normal IgG control was not affected by E2.
A similar recruitment pattern of these proteins was
observed on ER binding sites associated with the pro-
moters of other ERa target genes, CTSD and GREB1
Nucleic Acids Research, 2011,Vol.39, No. 16 6935(Supplementary Figure S3F). ChIP experiments with
sequential immunoprecipitation (ChIP and ReIP)
demonstrated that DBC1 and CCAR1 exist in the same
complex on the pS2 promoter (Figure 3B). Thus, E2
induces DBC1–CCAR1 complex formation on the pS2
promoter. However, on ER binding sites associated with
the PgR gene, little or no recruitment of CCAR1 and
DBC1 was detected under the same condition, whereas
ERa, AIB1 and CoCoA were recruited to the ER
binding sites associated with the PgR gene (Figure 3A).
Only background signals were observed with or without
E2 treatment for binding of the same proteins to an irrele-
vant site 1kb downstream from the transcription start site
of the PgR gene. These results are consistent with the data
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Figure 2. DBC1 is required for ERa function and estrogen-dependent growth of MCF-7 cells. (A) MCF-7 cells were transfected with 40pmol of
DBC1 siRNA#1 (siDBC1) or NS siRNA duplex. After 48h transfection, cells were treated with 100nM E2 or untreated and harvested after an
additional 24h. Total RNA was examined by real-time qRT–PCR analysis with primers speciﬁc for the indicated mRNAs. Results shown were
normalized to b-actin mRNA levels and are means±SD (n=3). (B and C) MCF-7 cells infected with lentiviruses encoding a NS or CCAR1 shRNA
were transfected with siDBC1#1 or siNS and treated or untreated with E2 as in A. Protein levels were monitored by immunoblot using the indicated
antibodies. The indicated mRNA levels were determined by real time qRT–PCR as in A. (D) MCF-7 cells infected with lentiviruses encoding a NS or
DBC1 shRNA were cultured in the absence or presence of 10nM E2 for 8 days. Cell viability was determined by MTT assay. Data are means±SD
(n=6). P-value was determined by Student’s t-test.
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gene expression (Figure 2C) and strongly suggest that
DBC1 and CCAR1 are directly involved in E2 induction
of a speciﬁc subset of ERa target gene expression.
To further test the role of DBC1 as an ERa
co-activator, we examined the effect of DBC1 depletion
on the recruitment of ERa to its target promoters.
Reduction of DBC1 levels by shRNA had no measurable
effect on the cellular levels of ERa (Figure 3C). However,
depletion of DBC1 substantially compromised the E2-
dependent recruitment of ERa to the promoters of
target genes pS2, CTSD and GREB1 (Figure 3D).
Interestingly, DBC1 depletion had no effect on the recruit-
ment of ERa to the PgR enhancer. Thus, DBC1 is
required for optimal association of ERa with the target
promoters, and ERa occupancy at the PgR enhancer
bypasses the requirement of DBC1.
DBC1 inhibits SIRT1-mediated deacetylation of ERa
and repression of ERa activity
ERa is acetylated by p300, and the acetylation enhances
DNA binding and transactivation activities of ERa (8).
SIRT1, an NAD-dependent protein deacetylase, has
been shown to deacetylate ERa (8). Furthermore, recent
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Figure 3. Recruitment of DBC1 to selective ERa target genes and requirement of DBC1 for optimal recruitment of ERa to the target promoters.
(A) ChIP assay. Crosslinked, sheared chromatin from MCF-7 cells treated with or without 100nM E2 (45min) was immunoprecipitated with the
indicated antibodies. qPCR analyses were performed using primers speciﬁc for the indicated promoters. The results are shown as percentage of input
and are means±SD (n=3). Numbers above the bars indicate fold increase in the promoter occupancy with E2 treatment. (B) ChIP and ReIP
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shRNA were treated with 100nM E2 for 45min. Protein levels were monitored by immunoblot using the indicated antibodies. ChIP assays using
ERa antibody were performed as described in A.
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its deacetylase activity (11,12). We ﬁrst examined the effect
of DBC1 expression on ERa deacetylation by SIRT1
in vivo. 293T cells were transfected with plasmids express-
ing GST-ER, HA-p300 and FLAG-SIRT1, and acetylated
levels of ERa were determined after immunoprecipitation
of ERa by immunoblots using anti-acetylated lysine
antibodies. As reported previously (8), the expression
of p300 strongly increased ERa acetylation, and
co-expression of SIRT1 dramatically reduced the
acetylated level of ERa (Supplementary Figure S4A and
Figure 4A). However, the deacetylation of ERa by SIRT1
was partially reversed by DBC1 expression (Figure 4A).
Similar results were observed in deacetylation assays
in vitro using puriﬁed acetylated ERa, SIRT1 and DBC1
(Figure 4B). To further conﬁrm the inhibitory role of
DBC1 in SIRT1-mediated deacetylation of ERa, endogen-
ous DBC1 expression was reduced by RNAi. As expected,
the levels of acetylated ERa were reduced by SIRT1 ex-
pression in a dose-dependent manner, and acetylated ERa
became more sensitive to deacetylation by SIRT1 in
DBC1-depleted cells (Figure 4C). These results strongly
support the role of endogenous DBC1 in inhibiting the
deacetylase activity of SIRT1 for ERa. In CoIP experi-
ments, SIRT1 interacted with ERa (Supplementary Figure
S4B), and SIRT1 binding to ERa was decreased when
DBC1 was co-expressed (Figure 4D). Similar results
were observed in GST pull-down assays (Supplementary
Figure S4C). These results indicate that DBC1 inhibits
SIRT1 activity, at least in part, by blocking the interaction
between ERa and SIRT1.
To assess further the roles of DBC1 and SIRT1 in ERa
activity, we determined the effects of SIRT1 on the tran-
scriptional activity of ERa.I nE R a reporter gene assays,
SIRT1, but not SIRT6 or SIRT7 (other nuclear sirtuins),
strongly repressed the transcriptional activity of ERa in a
dose-dependent manner (Figure 5A). Interestingly, a cata-
lytic mutant of SIRT1 (19), H363Y, also repressed ERa
activity, although slightly less efﬁciently than wild-type
SIRT1 (Supplementary Figure S4D). EX-527, a
SIRT1-speciﬁc inhibitor, partially rescued ERa activity
from SIRT1-mediated repression (Figure 5B). Thus the
repression of ERa by SIRT1 involves its deacetylase
activity but also appears to require other aspects of
SIRT1 function, such as protein–protein interactions.
DBC1 also blocked the inhibitory effect of SIRT1 on
ERa activity in a dose-dependent manner (Figure 5C).
In contrast, DBC1LZ (lacking the leucine zipper
region, residues 250–257), which fails to bind SIRT1 (11)
(Supplementary Figure S4E), failed to rescue the tran-
scriptional activity of ERa (Figure 5C). In addition, the
DBC1LZ mutant showed neither co-activator activity
nor synergy with CCAR1 (Figure 5D). These results
indicate that DBC1 inhibits SIRT1 activity through
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motif, the SIRT1-binding region, is also required for its
co-activator function and the cooperation with CCAR1.
SIRT1 represses the co-activator synergy between DBC1
and CCAR1 by competing with CCAR1 for binding
to DBC1
Because the LZ motif of DBC1 is important for its
co-activator function and synergy with CCAR1, we next
examined the ability of DBC1LZ mutant to interact with
CCAR1 (Figure 6A). CCAR1 interacted with DBC1
in vitro, but not with DBC1LZ mutant, indicating that
the LZ motif of DBC1 is required for the interaction not
only with SIRT1 but also with CCAR1. These results led
us to further test whether SIRT1 and CCAR1 compete
to bind to DBC1. Indeed, expression of SIRT1 (either
WT or H363Y mutant) dramatically reduced the inter-
action between CCAR1 and DBC1 in CoIP experiments
(Figure 6B). We next addressed whether the synergy
between CCAR1 and DBC1 is regulated by SIRT1.
Again, CCAR1 and DBC1 synergistically enhanced the
transcriptional activity of ERa in reporter gene assays,
but this synergistic cooperation was strongly inhibited
by SIRT1 in a deacetylase activity-independent manner
(Figure 6C). These results suggest that SIRT1 negatively
regulates the synergy between CCAR1 and DBC1 by
interfering with the interaction between CCAR1 and
DBC1.
DISCUSSION
Transcriptional regulation by DBC1
Transcriptional regulation is a dynamic process involving
association and dissociation of transcription factors with
gene-speciﬁc co-regulators at the target gene promoters
and post-translational modiﬁcations of components
of chromatin and the transcription complexes. In this
study, we identiﬁed DBC1 as a CCAR1-interacting
protein, and our results demonstrate that DBC1 functions
as an ERa co-activator. DBC1 enhanced the transcrip-
tional activity of ERa and cooperated synergistically
with CCAR1 (Figure 1), and depletion of DBC1 caused
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target genes (Figure 2A). Furthermore, simultaneous de-
pletion of DBC1 and CCAR1 caused further reduction of
ERa target gene expression (Figure 2C), demonstrating
the functional importance of the interaction between
DBC1 and CCAR1. DBC1 is recruited to the promoters
of native ERa target genes (Figure 3A and Supplementary
Figure S3F), and depletion of DBC1 protein attenuated
hormone-dependent growth and cell cycle progression
of breast cancer cells (Figure 2D and Supplementary
Figure S3E). These results ﬁrmly established DBC1 as
an ERa co-activator that plays an important physiological
role in ERa function in breast cancer cells. pS2 (also
known as trefoil factor 1, TFF1), CTSD (cathepsin D)
and GREB1 (gene regulated by estrogen in breast cancer
1) have been shown to promote tumor cell invasion, me-
tastasis and proliferation (20–22). PgR (progesterone
receptor), a member of NR superfamily, also plays a
critical role in tumor initiation and proliferation (23).
Interestingly, unlike p160 co-activators and CoCoA,
no signiﬁcant occupancy of DBC1 and CCAR1 was
observed on the estrogen-dependent enhancers of the
PgR gene (Figure 3A), which is consistent with the data
that neither single nor double depletion of DBC1 and
CCAR1 affected PgR gene expression (Figure 2C).
These ﬁndings suggest that DBC1 and CCAR1 regulate
the estrogen-induced expression of a subset, but not all,
of ERa target genes. Although the precise mechan-
ism underlying gene-speciﬁc recruitment of DBC1 and
CCAR1 is not fully understood, one intriguing possibility
is that sequences surrounding target ERa binding sites
determine DBC1 and CCAR1 recruitment to estrogen-
regulated promoters. Recently, cooperating transcription
factors such as FoxA1, Oct-1, C/EBPa have been reported
to play an important role in regulating ERa-dependent
transcription (24). The binding sites of these factors are
highly enriched near ERa binding sites, thus it is possible
that they may contribute to selective recruitment of
co-activators to ERa binding sites. Further study will be
needed to deﬁne the exact mechanism of gene-speciﬁc re-
quirement for DBC1 and CCAR1 in ERa-mediated
transcription.
It should be noted that a previous study showed that
DBC1 preferentially bound to and modulates the
steady-state level of unliganded but not liganded ERa
protein (17). However, in this report, we showed that
DBC1 interacts with ERa both in the presence and
absence of E2 (Supplementary Figure S1F and S1H) and
that DBC1 depletion using two different siRNA or
shRNA against DBC1 did not affect the level of
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Supplementary Figure S5). The reason for these conﬂict-
ing results is currently unknown. However, consistent with
our results, recent studies have also shown that DBC1
functions as a co-activator for NRs. DBC1 was identiﬁed
as an AR-interacting protein through a biochemical
approach (18). The interaction between DBC1 and AR
enhances the DNA binding activity of AR, thereby
enhancing the transcriptional activity of AR. DBC1 was
also found in NIF-1 (NRC interacting factor 1) complexes
(25). As a component of NIF-1 complex, DBC1 functions
as a co-activator for RARa. In other studies, DBC1 was
found to be involved in transcriptional repression. DBC1
associates with COUP–TFI complex, stabilizes the
interaction between NCoR and COUP-TFI, and thereby
contributes to COUP–TFI-mediated transcriptional re-
pression (26). DBC1 was also found to interact with
BRCA1 and repress the transcriptional activity of
BRCA1 (27). Another study reported that DBC1
suppresses the ligand-dependent transcriptional activation
function of ERb (28). Thus, the roles of DBC1 in tran-
scriptional regulation, positive and negative, are likely to
be very complex. It will be interesting to test whether the
mechanisms described in our study for DBC1 regulation
of ERa (interaction of DBC1 with CCAR1 or with
SIRT1, or the inhibition of NR deacetylation by SIRT1)
are responsible for the effects of DBC1 on the actions of
other NRs described above.
Reciprocal roles of DBC1 and SIRT1 in transcriptional
regulation
Acetylation of ERa enhances its DNA binding and tran-
scriptional activity and is reversed by the native cellular
deacetylases (8), suggesting reversible acetylation as a
modulator of ERa activity. Our study provides evidence
for an ERa regulatory pathway controlled reciprocally by
SIRT1 and DBC1. We showed that SIRT1 binds and
inhibits the transcriptional activity of ERa by regulating
acetylation of ERa (Figures 4 and 5). The ability of SIRT1
to deacetylate and repress ERa activity mechanistically
resembles the effects of SIRT1 on p53, FOXO, PGC1a
and AR (29), suggesting that SIRT1 plays a broad inhibi-
tory role in regulating the activity of various transcription
factors. Thus, one mechanism of the co-repressor function
of SIRT1 is to deacetylate and thereby inactivate ERa and
other transcription factors (Figure 6D). However, and im-
portantly, overexpression of SIRT1 H363Y mutant still
effected a signiﬁcant repression of ERa-mediated tran-
scription (Supplementary Figure S4D), which suggests
that SIRT1 may have another mechanism of action in
addition to deacetylating ERa. A recent study showed
that the deacetylase activity of SIRT1 may not be respon-
sible for all of the functions of SIRT1, suggesting that, in
some cases, the interaction of SIRT1 with other proteins
may be also important for its function (19). In this regard,
the present study showed that another mechanism of the
inhibitory function of SIRT1 is to block the interaction
between co-activators (Figure 6D). Our work demon-
strates that co-activator synergy between DBC1 and
CCAR1 can be regulated through a protein–protein
interaction (Figure 6). SIRT1 competes with CCAR1 for
binding to the LZ motif of DBC1. Consequently, the
interaction between DBC1 and CCAR1 is disrupted by
SIRT1, which results in repression of their synergy in tran-
scriptional activation by ERa. Thus, our results reveal
that SIRT1 is a critical regulator, which negatively regu-
lates physical interaction and functional synergy between
DBC1 and CCAR1, and suggest that SIRT1 can regulate
ERa function indirectly through disrupting co-activator
interaction in addition to acting directly through an
ERa deacetylation-dependent mechanism (Figure 6D).
Recent studies identiﬁed DBC1 as a regulator of several
proteins. DBC1 interacts with and functions as a negative
regulator of SIRT1 (11,12), SUV39H1 (30) and HDAC3
(31). As a SIRT1 inhibitor, DBC1 binds to the SIRT1
catalytic domain and inhibits p53 deacetylation by
SIRT1, leading to upregulation of p53 function and
increase of p53-mediated apoptosis induced by genotoxic
stress. DBC1 also binds to catalytic domains of SUV39H1
and HDAC3 and inhibits their histone methyltransferase
and deacetylase activities. Thus, DBC1 may be an import-
ant regulator of a wide variety of cellular processes
including gene expression, chromatin remodeling, cell pro-
liferation, apoptosis and metabolism. Here, we showed
several lines of evidence that DBC1 negatively regulates
SIRT1-mediated deacetylation and repression of ERa.
SIRT1-mediated ERa deacetylation was inhibited by
DBC1 overexpression but stimulated by DBC1 knock-
down (Figure 4). DBC1 repressed SIRT1 activity
through blocking the interaction between SIRT1 and its
substrate ERa (Figure 4D and Supplementary Figure
S4C), and the SIRT1-mediated repression of ERa was
reversed by DBC1 expression (Figure 5C). In addition,
our ChIP analyses revealed that DBC1 is required for ef-
ﬁcient recruitment of ERa to its target promoters (Figure
3D), probably through inhibiting SIRT1-mediated
deacetylation of ERa. These results are consistent with
the previous report that acetylation of ERa enhances its
DNA binding activity (8). It is also possible that ERa
binds to its target DNA more efﬁciently when complexed
with DBC1. Importantly, our previous ChIP analyses
demonstrated that the inhibition of CCAR1 recruitment
to the pS2 promoter had no observable effect on recruit-
ment of ERa (5). These results indicate that, despite the
sequence similarity between DBC1 and CCAR1, these two
co-activators likely have distinct functions. In addition,
the fact that their cooperation for ERa-mediated tran-
scription is not additive but synergistic suggests that
each co-activator makes a distinct contribution to the
transcriptional activation process: CCAR1 contributes to
transcriptional activation by coordinating actions of p160
and Mediator complexes; DBC1 enhances the DNA
binding activity of ERa by regulating the acetylation
state of ERa. Consistent with our observations, a recent
study reported that DBC1 acts as an AR co-activator and
is required for efﬁcient binding of AR to the target pro-
moters (18). It will be interesting to test whether DBC1
enhances AR DNA binding activity by inhibiting
SIRT1-mediated deacetylation of AR.
Interestingly, during the preparation of this article, it
was reported that over 70% of breast cancer tissues
Nucleic Acids Research, 2011,Vol.39, No. 16 6941express a high level of DBC1 and that DBC1 expression is
signiﬁcantly associated with short overall and relapse-free
survival (13). These results support our ﬁndings that
DBC1 plays a critical role in the regulation of ERa and
SIRT1 function and hormone-dependent growth of breast
cancer cells. However, the same report also showed that
DBC1 expression was positively correlated with SIRT1
expression. Although the underlying mechanism and sig-
niﬁcance for this correlation is currently unknown, it is
possible that cells express more SIRT1 to balance or
better control the DBC1 function when the DBC1
function becomes higher. Consistent with this idea,
SIRT1 expression is transcriptionally induced by E2F1
(32), which is known as one of the ERa target genes
(33). Also of note is that resveratrol, a SIRT1 activator,
has been shown to inhibit estrogen-dependent growth of
breast cancer cells (34). Taken together, with the fact that
ERa signaling is oncogenic to the breast, it is likely that
upregulation of DBC1 could lead to an enhanced ERa
function, thus accelerating the development and progres-
sion of breast cancer. In conclusion, our ﬁndings support
and extend previous observations that DBC1 is a negative
regulator of SIRT1, establish reciprocal roles of DBC1
and SIRT1 in regulating ERa function, and provide new
insight into the regulatory mechanism of co-activator
synergy. It would be interesting to determine whether
DBC1 and SIRT1 reciprocally regulate the transcriptional
activity of other NRs and co-activator synergy through a
similar mechanism.
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